Mallinckrodt (NYSE: MNK) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for PENNSAID® (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal ...
Canada-based pharmaceutical company Nuvo Research has received US Patent relating to compositions and methods of using WF10 and new derivative formulations for the treatment of allergic asthma, allergic rhinitis and atopic dermatitis. ...
Tags: Nuvo Research, Drug Candidate
Specialty pharmaceutical company Nuvo Research has announced the launch of Pliaglis (lidocaine and tetracaine) cream 7%/7% by Galderma in Europe. Galderma has worldwide marketing rights for Nuvo's Pliaglis, a topical local anesthetic ...
Tags: Nuvo Research, Pliaglis
Nuvo Research has announced the launch of Pliaglis (lidocaine and tetracaine) topical local anesthetic cream 7%/7% by Galderma Pharma in the US. Pliaglis is indicated for local analgesia for superficial aesthetic procedures including ...
Tags: Pharma, Galderma, Galderma Pharma
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Nuvo Research's US licensing partner, Mallinckrodt, following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical ...
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Nuvo Research's Pliaglis (lidocaine/tetracaine) 7%/7% cream. Pliaglis, a topical local anesthetic cream forms a pliable peel on the skin ...
The United States Patent Office has issued a patent covering Nuvo Research's compositions and methods of using Pennsaid (diclofenac sodium topical solution) 2.0% w/w (Pennsaid 2% Patent), which will expire on 21 April 2028. Pennsaid is a ...